Response to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is monitored by quantification of BCR::ABL1 transcript levels. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.